Hubei Cancer Hospital

Recent papers from Hubei Cancer Hospital

1. Liposomal irinotecan and capecitabine plus bevacizumab as second‐line therapy in metastatic colorectal cancer: A multicenter, single‐arm studyCancer · 2026
2. Therapeutic potential of escin and its nanoparticle formulations in cancer -a systematic review and meta-analysis of preclinical studyFrontiers in Pharmacology · 2026
3. CACA guidelines for holistic integrative management of PET imagingHolistic Integrative Oncology · 2026
4. Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non−Small Cell Lung CancerJAMA Oncology · 2026
5. Trastuzumab Rezetecan in ERBB2-Low Advanced Breast CancerJAMA · 2026
6. The nucleolar deubiquitinase OTUD4 coordinates spatial organization of perinucleolar heterochromatin to restrain tumor immunogenicityNature Communications · 2026
7. Camrelizumab plus famitinib as first-line treatment for locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE): a multi-center, single-arm, phase 2 trialEClinicalMedicine · 2026
8. AI-driven quantitative assessment of abdominal organs and immunotherapy outcomes across multicenter hepatocellular carcinoma cohortsnpj Precision Oncology · 2026
9. Automated ultrasound computed tomography for breast mass screening: A multicenter studyEngMedicine · 2026
10. Safety, efficacy, and biomarker analysis of HTMC0435 plus temozolomide in relapsed extensive-stage small-cell lung cancer: A phase Ib/II trialBMC Medicine · 2026
11. Associations between endoscopic findings and clinicopathological characteristics in primary gastrointestinal lymphoma: a single-center retrospective studyScandinavian Journal of Gastroenterology · 2026
12. Latent Class Analysis–Derived Classification and Cancer-Specific Death in Endometrial Carcinoma: A Population-Based Cohort StudyJCO Precision Oncology · 2026
13. HSP27 Provides Stress-Adaptive Proteostasis Buffering in Glioblastoma and Is Therapeutically VulnerableCells · 2026
14. Profiling EGFR , c‐ MET , and B7H3 co‐expression to guide next‐generation dual‐drug conjugate strategies in colorectal cancerThe Journal of Pathology Clinical Research · 2026
15. Response-Adapted Postoperative Therapy Following Neoadjuvant Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: a phase II trialNature Communications · 2026
16. Risk Factors for Pneumonitis Induced by Combined Radiotherapy and Immunotherapy: A Multicenter Prospective StudyJournal of the National Comprehensive Cancer Network · 2026
17. Core-shell Au@HOF nanoradiosensitizers activate potent immunogenic cell death for enhanced radio–radiodynamic–immunotherapyJournal of Nanobiotechnology · 2026
18. First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2–Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)Journal of Clinical Oncology · 2026
19. Transformer‐Based Multitask Framework Integrating Habitat and Deep Learning for Predicting Early Disease Control and Survival in Immunotherapy‐Treated Hepatocellular CarcinomaAdvanced Science · 2026
20. Fibrotic mechanobiological microenvironments drive mechano-immune exclusion and immunotherapy resistance in breast cancer: mechanisms, stratification and therapeutic opportunitiesInternational Immunopharmacology · 2026